$NAGE News

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience Announces Availability Of Its Healthy-Aging NAD+ Supplement Tru Niagen On Walmart.com

Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Niagen Bioscience, Inc. 2026 Q2 - Results - Earnings Call Presentation

Niagen Bioscience Says It Expects Full-Year Ingredient Business Below Prior Year As Commercial Partners Face More Competitive Market; Sees Niagen Plus And New Skincare Partnerships Contributing Beginning 2027

Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M Est

Niagen Bioscience Q2 EPS $0.01 Misses $0.02 Estimate, Sales $29.785M Miss $30.690M Estimate

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging

Aging Cell Publishes Study In 'Aging Cell' Showing Niagen NR Supplementation Reduces Muscle Biological Aging and Supports Healthy Muscle Function

Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference

Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research

Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program - Slideshow

Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Niagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia Telangiectasia